Patents by Inventor Albert John Molinari

Albert John Molinari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenanthridine carbonyl phenols
    Patent number: 7585871
    Abstract: The present invention relates generally to phenanthridine carbonyl compositions such as substituted phenanthridine carbonyl phenols of Formula 1: wherein R1 to R15 are as defined in the specification, or pharmaceutically acceptable salts thereof; and methods of using them.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Robert John Steffan, William Jay Moore, Eugene J. Trybulski, Albert John Molinari
  • NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
    Publication number: 20090054392
    Abstract: The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-?-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
    Type: Application
    Filed: August 19, 2008
    Publication date: February 26, 2009
    Applicant: Wyeth
    Inventors: Jeffrey Claude Pelletier, Luciana de Araujo Felix, Daniel Michael Green, Diane Barbara Hauze, Joseph Theodore Lundquist, IV, Charles William Mann, John Francis Mehlmann, John Francis Rogers, JR., Matthew Douglas Vera, Albert John Molinari
  • Substituted dihydrophenanthridinesulfonamides
    Patent number: 6894061
    Abstract: This invention provides a compound of formulae (I) or (II) having the structure or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 17, 2005
    Assignee: Wyeth
    Inventors: Albert John Molinari, Mark Antony Ashwell, Brian Hugh Ridgway, Amedeo Arturo Failli, William Jay Moore
  • Substituted dihydrophenanthridinesulfonamides
    Publication number: 20040167155
    Abstract: This invention provides a compound of formulae (I) or (II) having the structure 1
    Type: Application
    Filed: November 20, 2003
    Publication date: August 26, 2004
    Inventors: Albert John Molinari, Mark Antony Ashwell, Brian Hugh Ridgway, Amedeo Arturo Failli, William Jay Moore
  • Heterocyclic beta-3 adrenergic receptor agonists
    Patent number: 6605618
    Abstract: This invention provides compounds of Formula I having the structure wherein,  U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: August 12, 2003
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari
  • Heterocyclic beta-3 adrenergic receptor agonists
    Publication number: 20030018045
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: July 2, 2002
    Publication date: January 23, 2003
    Applicant: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari
  • Heterocyclic &bgr;-3 adrenergic receptor agonists
    Patent number: 6451814
    Abstract: This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: September 17, 2002
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari